Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.
Short Term Liabilities: AMRN's short term assets ($848.1M) exceed its short term liabilities ($229.7M).
Long Term Liabilities: AMRN's short term assets ($848.1M) exceed its long term liabilities ($41.3M).
Debt to Equity History and Analysis
Debt Level: AMRN's debt to equity ratio (10.1%) is considered satisfactory.
Reducing Debt: AMRN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: AMRN has a low level of unsold assets or inventory.
Debt Coverage by Assets: AMRN's debt is covered by short term assets (assets are 14.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AMRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Amarin's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Amarin's salary, the management and board of directors tenure and is there insider trading?
3.9yrs
Average management tenure
CEO
JohnThero(58yo)
5.9yrs
Tenure
US$4,205,779
Compensation
Mr. John F. Thero has been the Chief Executive Officer of Amarin Corporation Plc since January 1, 2014 and has been its President since November 2010. Mr. Thero serves as the President of U.S. at Amarin Co ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD4.21M) is below average for companies of similar size in the US market ($USD6.81M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.9yrs
Average Tenure
52.5yo
Average Age
Experienced Management: AMRN's management team is considered experienced (3.9 years average tenure).
Board Age and Tenure
9.9yrs
Average Tenure
69yo
Average Age
Experienced Board: AMRN's board of directors are considered experienced (9.9 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead prod ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/07 23:31
End of Day Share Price
2019/12/06 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.